Predictive markers and prenatal management of isolated fetal complete atrioventricular block: <scp>A</scp> retrospective review at a single institution

Murakami, Keisuke; Yamamoto, Yuka; Fukunaga, Hideo; Matsushita, Masakazu; Hirai, Chihiro; Makino, Shintaro; Shimizu, Toshiaki; Itakura, Atsuo; Takeda, Satoru

doi:10.1111/jog.13511

Cited by 1 publication

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been confirmed that the earlier subjective symptoms of ICP appear (itching of the skin), then the risk of an early delivery happening increases, which could be a result of the unfavorable effects of bile acids on the fetus being elongated (Murakami et al, ). On the basis of previous research, it has been determined that a statistically significant increased risk of an early delivery happening as well as the occurrence of serious fetal damage occurs when the bile acid levels passes 40 μmol/l in the blood (Glantz, Marschall, Lammert, & Mattsson, ).…”

Section: Discussionmentioning

confidence: 93%

Effect of ursodeoxycholic acid therapy due to pregnant intrahepatic cholestasis on chemerin and irisin levels

Dąbrowski¹,

Kierach²,

Grabarek³

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

The purpose of the work was to assess changes in chemerin and irisin levels in women with diagnosed intrahepatic cholestasis of pregnant women treated with ursodeoxycholic acid. The study group consisted of 50 patients with diagnosed and confirmed intrahepatic cholestasis of pregnant women at 24–25 weeks of pregnancy treatment by ursodeoxycholic acid (UDCA). The study also included a group of 40 pregnant women, without concomitant intrahepatic cholestasis of pregnancy (ICP). In the pregnant ICP group, whole blood was collected 4 times: before the first dose of drug, 4 and 8 weeks after the first dose, and day after delivery. It was observed that statistically significant differences in the concentration of irisine occur between the time before starting treatment and the 8‐week therapy and 1 day after delivery. The Pearson correlation analysis (r's) showed two statistically significant relationships (p < .05). The first of these can be found between the concentration of irisine and chemerin in the group of nonpregnant women and the second in the group of patients with intrahepatic pregnant cholestasis before the first dose of UDCA. A significant relationship between irisin and chemerin concentrations was confirmed in the group of pregnant ICP patients during UDCA acid therapy and among healthy pregnant women.

show abstract

Section: Discussionmentioning

confidence: 93%

Effect of ursodeoxycholic acid therapy due to pregnant intrahepatic cholestasis on chemerin and irisin levels

Dąbrowski¹,

Kierach²,

Grabarek³

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

Predictive markers and prenatal management of isolated fetal complete atrioventricular block: A retrospective review at a single institution

Abstract: An anti-Ro level of 32× could be the threshold value for CAVB development. Prenatal anti-inflammatory treatment in patients with CAVB and prophylactic PEX in patients who had an affected child may have the potential to improve pregnancy outcomes.

Cited by 1 publication

References 17 publications

Effect of ursodeoxycholic acid therapy due to pregnant intrahepatic cholestasis on chemerin and irisin levels

Effect of ursodeoxycholic acid therapy due to pregnant intrahepatic cholestasis on chemerin and irisin levels

Contact Info

Product

Resources

About